Ribon Therapeutics is a biotechnology company developing first-in-class therapeutics targeting novel enzyme families activated under cellular stress conditions that contribute to disease. We are exploring novel areas of biology to develop effective treatments for patients with limited therapeutic options. Leveraging a chemical biology approach and our proprietary discovery platform, we are building a pipeline of selective, small molecule inhibitors to numerous NAD+ utilizing enzymes, beginning with monoPARPs, which have applications across multiple therapeutic areas. Our lead program is developing PARP7 inhibitors for the treatment of cancer.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 01/04/19 | $65,000,000 | Series B |
Celgene Corporation Deerfield Management Company, L.P. Johnson & Johnson Development Corporation (JJDC) Novartis Venture Funds  Osage University Partners Takeda Ventures The Column Group US Venture Partners | undisclosed |
